Exelixis Inc (EXEL)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$41.29

Buy

$43.73

arrow-up$1.15 (+2.68%)

Prices updated at 01 Apr 2026, 13:30 EDT

Prices minimum 15 mins delay

Prices in USD

Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.

NASDAQ

1.16%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Dr. Stelios Papadopoulos,PhD

CEO

Dr. Michael M. Morrissey, PhD

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

1,077

Head office

1851 Harbor Bay Parkway

Alameda

United States

94502

+1 650 837-7000

shubbard@exelixis.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. George H. Poste, D.V.M.,F.R.S.,PhD Independent Director	0.10m
Mr. Jack L. Wyszomierski, M.S. Independent Director	0.10m
Dr. Michael M. Morrissey, PhD Director, President and Chief Executive Officer	1.25m
Dr. Stelios Papadopoulos,PhD Chairman of the Board	0.13m
Mr. David E. Johnson Independent Director	0.09m
Dr. Mary C. Beckerle, PhD Independent Director	0.08m
Dr. Maria C. Freire, PhD Independent Director	0.10m
Ms. Julie Anne Smith Independent Director	0.10m
Mr. Jeffrey J. Hessekiel Executive Vice President and Secretary	0.65m
Mr. Christopher J. Senner Executive Vice President, Chief Financial Officer and Principal Accounting Officer	0.79m
Mr. Tomas J. Heyman Independent Director	0.09m
Dr. Sue Gail Eckhardt, M.D. Independent Director	0.08m
Dr. Dana T. Aftab, PhD Executive Vice President, Research and Development	0.62m
Mr. Robert Oliver, M.B.A. Independent Director	0.08m
Dr. Brenda Hefti, J.D.,PhD General Counsel	-
Mr. Patrick J. Haley Executive Vice President, Commercial	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	29,366,959
Vanguard Group Inc	25,490,449
BlackRock Fund Advisors	17,635,157
Fuller & Thaler Asset Management Inc	15,921,792
Farallon Capital Management, L.L.C.	15,709,500

Director dealings

Date chevron-l-regular chevron-r-regular	Action
03 Dec 2025	-
21 Nov 2025	-
21 Nov 2025	-
20 Nov 2025	-
20 Nov 2025	-
20 Nov 2025	-
17 Nov 2025	-
12 Nov 2025	-
12 Nov 2025	-
11 Nov 2025	-
12 Nov 2025	-
12 Nov 2025	-
11 Nov 2025	-
11 Nov 2025	-
11 Nov 2025	-
11 Nov 2025	-
11 Nov 2025	-
08 Oct 2025	-
03 Jun 2025	-
02 Jun 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.